Phoenicia BioSciences’ Chief Medical Officer. Dr. Susan Perrine, has received notice of approval of a 20th US Patent, 10,111, 846 B2 awarded on October 30, 2018. This oral therapeutic prolonges survival in irradiated mice following fatal irradiation in a study conducted by AFFRI, the Armed Forces Radiobiology Institute, with only a few days’ of oral ST7S treatment. ST7S enhances recovery of white blood cells, platelets, and red blood cells after marrow suppression in several systems.
Phoenicia is seeking partners to co-develop this therapeutic.
December 14, 2018 Phoenicia BioSciences has received notice of approval of their application for Orphan Drug Designation for product PB-04 in the European Union. Orphan Drug Designation allows 12 years of market exclusivity following marketing approval for a new drug for treatment of adult and pediatric orphan populations.
Phoenicia BioSciences’ CMO Dr. Susan Perrine has received notice that a 20th US Patent, Number 10,111,846 B2 was approved on October 30, 2018 for a therapeutic candidate designated ST7S, a small molecule which dramatically stimulates white blood cell proliferation and other blood cell lineages following radiation and has prolonged survival in radiated mice, in studies by AFFRI, the Armed Forces Radiobiology Research Institute.
The mission of Phoenicia Biosciences is to advance the development and translation of therapies for serious medical conditions for which current treatments are inadequate or lacking, particularly diseases affecting global populations.